Application of oxymetazoline

PreclinicalSmall molecule

Application of oxymetazoline is one of 3 small molecule programs targeting Nasal Obstruction. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasal ObstructionCompleted

Nasal ObstructionPreclinical

Completed

Competition

Competitive Landscape

2 competitors in Nasal Obstruction

#DrugCompanyPhaseTrials

Pulmicort

SSalix

Phase 2

1 2

Rhofade

KKenvue Brands

Phase 2

1 3

Application of oxymetazoline

MMayo Clinic

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nasal Obstruction1 trial

The Effect of Nasal Hair on Nasal Obstruction

Completed·MMayo Clinic·N/A·NCT01850511·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Application of oxymetazoline. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Application of oxymetazoline compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Application of oxymetazoline. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMayo Clinic

Application of oxymetazoline

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nasal Obstruction1 trial

References

Drug Info

Quick Facts

Related News